The Role of Interleukin-6 Family Members in Cardiovascular Diseases

Yongqi Feng1,2,3†, Di Ye1,2,3†, Zhen Wang1,2,3, Heng Pan1,2,3, Xiyi Lu1,2,3, Menglong Wang1,2,3, Yao Xu1,2,3, Junping Yu1,2,3, Jishou Zhang1,2,3, Mengmeng Zhao1,2,3, Shuwan Xu1,2,3, Wei Pan1,2,3, Zheng Yin1,2,3, Jing Ye1,2,3* and Jun Wan1,2,3*

1 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China, 2 Cardiovascular Research Institute, Wuhan University, Wuhan, China, 3 Hubei Key Laboratory of Cardiology, Wuhan, China

Cardiovascular disease is one of the main causes of human mortality. Cytokines play crucial roles in the development of cardiovascular disease. Interleukin (IL)-6 family members are a series of cytokines, including IL-6, IL-11, IL-30, IL-31, OSM, LIF, CNTF, CT-1, CT-2, and CLC, that regulate multiple biological effects. Experimental and clinical evidence shows that IL-6 family members are closely related to cardiovascular diseases such as atherosclerosis, hypertension, aortic dissection, cardiac fibrosis, and cardiomyopathy. This review mainly discusses the role of IL-6 family members in cardiovascular disease for the sake of identifying possible intervention targets for cardiovascular disease prevention and treatment.

Keywords: cardiovascular diseases, IL-6 family cytokines, atherosclerosis, coronary artery disease, cardiac remodeling

INTRODUCTION

Currently, cardiovascular diseases (CVDs) are the leading cause of human death and morbidity worldwide. They not only threaten the safety and quality of life of patients but also place a heavy burden on society (1, 2). Inflammation plays an important role in CVD, and markers of inflammation can predict future CVD events (3).

The interleukin-6 family comprises IL-6, IL-11, IL-30, IL-31, and non-IL molecules, including oncostatin M (OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotoxin 1 (CT-1), and cardiotoxin-like cytokine (CLC). They are characterized by sharing the common receptor subunit glycoprotein 130 (gp130) and sharing the structure of four-helices with an up-up–down-down topology.

A large number of studies have confirmed that IL-6 has both proinflammatory and anti-inflammatory effects via different IL-6Rs. The receptor complexes of IL-6 are composed of IL-6R or soluble IL-6R and gp130. It seems that the proinflammatory effect mainly relies on trans-signaling mediated by sIL-6R and that the anti-inflammatory effect mainly depends on membrane-bound IL-6R (4–7). IL-6 induces Th17 differentiation, suppresses Treg differentiation, and stimulates the polarization of M2 macrophages (8–10). Lymphocytes, monocytes/macrophages, adipocytes, and hematopoietic and endothelial cells are the cellular sources of IL-6 (11). The gp130 protein is expressed in almost all tissues (12).

IL-11 is reported as a pro- and anti-inflammatory cytokine. The signal transduction process of IL-11 is similar to that of IL-6, and the IL-11/IL-11R complex needs to be formed before gp130 can be activated. Additionally, there are both classic and trans-signaling pathways through IL-11R or sIL-11R complexes (13, 14). The cellular sources of IL-11 are T cells, B cells, macrophages, cardiac myocytes, etc. The main source of IL-11 is not clear. It can induce Th2 and Th17 differentiation, suppress Th1 differentiation and inhibit macrophage activity (13).
IL-30 is the p28 subunit of IL-27 but has some functions that are independent of IL-27. IL-30 is a natural antagonist of gp130, so IL-30 may offer a therapeutic strategy against inflammation (15, 16). IL-30 has been shown to inhibit the differentiation of Th1 and Th17 cells (17). IL-30 is secreted by activated macrophages and splenocytes (18).

IL-31 is a proinflammatory cytokine that activates the receptor complex of IL-31RA and OSMR. IL-31 induces Th1 and inhibits Th17 differentiation in vitro (19, 20). IL-31 is secreted by T cells and granulocytes, especially Th2 cells (21).

OSM has been shown to bind to both the gp130/OSMR complex and gp130/LIFR complex and shows proinflammatory effects (22–24). In vitro experiments have shown that OSM inhibits the proliferation of Th17 cells and induces dendritic cell (DC) maturation and Th1 polarization (25, 26). It is secreted by activated monocytes/Møs, DCs, neutrophils, T lymphocytes, and hematopoietic cells in the bone marrow (22).

LIF is an anti-inflammatory cytokine that binds to the gp130/LIFR complex (27). LIF is highly produced by Treg cells in both humans and mice. LIF inhibits inflammation by promoting Treg differentiation and inhibiting Th17 cell differentiation (28).

CNTF binds to CNTFR and then induces heterodimerization of gp130 and LIFR, which is involved in signal transduction (29). The cellular source and its role in the immune response remain to be studied.

CT-1 plays an anti-inflammatory role and binds to the complex of gp130 and LIFR and possibly requires the CT-1R subunit in neuronal cells (30, 31). CT-1 mRNA is expressed in the adult human heart, skeletal muscle, ovary, colon, prostate, and testis. CT-1 is mainly secreted by cardiac nonmyocytes in the heart. However, the cellular source still needs to be studied (31–33).

CLC or the heterodimeric cytokine cardiotrophin-like cytokine/cytokine-like factor-1 (CLC:CLF-1) binds to CNTFR and then interacts with gp130/LIFR, which subsequently has a proinflammatory role (34–36). Evidence has shown that CLC is secreted by circulating lymphocytes and can stimulate B cells, activate Møs, and promote monocyte numbers (37–39).

The signaling pathways of IL-6 family members are similar but distinct because of their similar but distinct receptor complexes. One major signaling pathway is the activation of Janus kinase (JAK) tyrosine kinase family members, leading to the activation of the signal transducers and activators of transcription (STAT) transcription factors, mostly STAT3. Another major signaling pathway is the JAK-SH2 domain tyrosine phosphatase 2 (SHP2)-mitogen-activated protein kinase (MAPK) pathway (23, 40–43). The detailed pathways are illustrated in Table 1.

**INTERLEUKIN-6 FAMILY MEMBERS AND CARDIOVASCULAR DISEASE**

Increasing evidence demonstrates that inflammation plays an important role in the development of cardiovascular disease (51–54). IL-6 family members modulate the immune response and inflammatory activity and then participate in the development of cardiovascular diseases (41, 55, 56).

**INTERLEUKIN-6 FAMILY MEMBERS AND Atherosclerosis, Coronary Artery Disease**

Atherosclerosis is the leading cause of coronary artery disease (CAD). It causes life-threatening events such as thrombosis as well as the rupture or erosion of atherosclerotic plaques (57). Atherosclerosis is a chronic inflammatory disease, so many researchers have focused on the potential mediators that initiate and maintain this vascular disease (58). The progression of carotid atherosclerosis is positively correlated with the elevation of IL-6 (59). IL-6 plays an important role in regulating the downstream inflammatory responses that contribute to the development of atherosclerosis (60, 61). IL-6 perpetuates vascular inflammation by promoting smooth muscle cell (SMC) proliferation and migration, endothelial dysfunction and the recruitment and activation of inflammatory mediators, which result in atherosclerotic plaque development and plaque destabilization (61, 62). Higher IL-6 measured at 24 h after STElevation myocardial infarction (STEMI) is associated with a larger infarct size and diminished cardiac function measured at 4 months. IL-6 can be a potential biomarker for STEMI prognosis and a target for improving prognosis (63). Clinical data show that IL-6 is a biomarker of mortality from unstable CAD (64). The increase in IL-6 levels has a strong relationship with future cardiac events and CAD mortality in anginal syndrome or healed myocardial infarction patients (65). The use of tocilizumab, an IL-6 receptor antagonist, reduces the inflammatory response in non-STEMI (NSTEMI) patients, which may be beneficial to patients but still needs further study (66). Canakinumab is a monoclonal antibody against IL-1β and can modulate the IL-6 pathway to decrease the major adverse cardiovascular event (MACE) rate (67). On the one hand, experimental atherosclerosis studies show that treatment with recombinant IL-6 (rIL-6) promotes early atherosclerosis in C57BL/6 and ApoE-deficient mice. The rIL-6-treated mice showed higher plasma levels of proinflammatory cytokines such as TNFα and IL-1β, which can promote the development of fatty streaks by enhancing the accumulation of foam cells. In addition, proinflammatory cytokines can activate macrophage-monocytes so that cell migration into the intima, lipid uptake, and low-density lipoprotein (LDL) oxidation are increased (68). On the other hand, IL-6 has an atheroprotective effect because lifetime IL-6 deficiency leads to more severe atherosclerosis rather than inhibition of plaque formation. It is believed that lifetime deficiency of IL-6 breaks the balance of IL-6 and IL-10 and thus promotes the development of atherosclerosis (69, 70). OSM is expressed in atherosclerotic lesions and promotes SMC proliferation, migration and extracellular matrix synthesis, which may contribute to atherosclerosis progression. OSMR-β deficiency ameliorates atherosclerosis and plaque instability. Serum OSM levels are elevated in CAD patients compared to those without CAD (71–73). Nevertheless, chronic administration of OSM can attenuate the development of plaques and improve plaque severity in APOE*3Leiden.CETP mice. The possible mechanisms might involve regeneration of the endothelial barrier, induction of SMC proliferation, and a reduction in the inflammatory Ly-6CHigh monocyte subset. Patients with higher serum OSM have increased post incident coronary heart
The formation of macrophage-foam cells. A murine experiment mechanism of the increase in lipoprotein uptake, inducing scavenger receptor A1 (SR-A1) expression, which is the major disease survival probability \((74)\). Because OSM can activate both gp130/OSMR receptor complex and gp130/LIFR receptor complex. The selective inhibition of OSMR-β might be a potential therapeutic target. Further study is needed. In a rabbit model, LIF can retard the progression of atherosclerosis because it can reduce macrophages in the neointima of uninjured arteries and can regulate iNOS activity to maintain beneficial levels of nitric oxide (NO) \((75, 76)\). CT-1 promotes the development of atherosclerotic lesions because it can induce the migration and proliferation of vascular smooth muscle cells and collagen-1 production. It can stimulate inflammatory responses, and the formation of foam cells is correlated with CD36 and ACAT1 upregulation in macrophages \((77)\). ApoE and CT-1 double knockout (DKO) mice have smaller atherosclerotic lesions than ApoE KO mice. CT-1 deficiency induces atheroprotective immune cells, including Bregs, Tregs and B1a cells. Moreover, CT-1 deficiency is beneficial to plaque stability because DKO mice have an increased collagen content in the aortic sinus, a significant reduction in MMP9 expression and necrotic core area and an increase in the fibrous cap thickness in atherosclerotic roots. The present study demonstrates the inhibitor of CT-1 attenuates atherosclerosis progression and development. But the application in patients still needed to be studied \((78)\). Cardiotrophin-like cytokine factor 1 (CLCF1) upregulates scavenger receptor A1 (SR-A1) expression, which is the major mechanism of the increase in lipoprotein uptake, inducing the formation of macrophage-foam cells. A murine experiment indicated that SR-A1 deficiency decreased atherosclerotic lesions \((44, 79)\). Kim, Jun W et al. have engineered CLCF1 variants that can inhibit or activate CNTFR. The application of it in atherosclerosis might be meaningful research \((80)\).

### Interleukin-6 Family Members and Hypertension

Hypertension is a leading cause of cardiovascular events, which contributes greatly to mortality and disability. With the increased understanding of immunology, evidence that the immune system may lead to hypertension is increasing \((81)\).

The inhibition of IL-6 attenuates the development of salt-sensitive hypertension in rat models. IL-6 KO mice have a lower mean arterial pressure (MAP) than WT mice. The deletion of IL-6 can prevent the activity of the JAK2/STAT3 pathway, which plays a role in Ang II-induced hypertension \((82–84)\). The circulating levels of IL-6 have a positive relationship with blood pressure \((85)\). Clinical data indicates that the hypomethylation of the IL-6 gene promoter may increase the risk of essential hypertension by upregulating the expression of IL-6 \((86)\). CT-1 is significantly increased in untreated hypertensive patients compared with normotensive subjects \((87, 88)\). SA study showed that excess CT-1 may contribute to inappropriate left ventricular growth in hypertension patients \((89)\). Research on other IL-6 family members associated with hypertension remains to be conducted. Aortic stiffness is measured by pulse wave.

#### Table 1: The receptor complexes and pathways of IL-6 family members.

| Receptors complexes | Pathways | Role in immune response | Cellular source | References |
|---------------------|----------|-------------------------|----------------|------------|
| **IL-6**            | IL-6R/sIL-6R+gp130 | JAK1, JAK2, TYK2, STAT3, STAT5, MAPK, PI3K | Induce Th17 differentiation Suppress Treg differentiation stimulate the polarization of Mø | Lymphocytes, monocytes/ Mø, adipocytes, hematopoietic and endothelial cells | (5–11, 44–47) |
| **IL-11**           | IL-11R/sIL-11R+gp130 | JAK, STAT3, MAPK, PI3K | Induce Th2, Th17 differentiation Suppress Th1 differentiation Inhibit Mø activity | T cells, B cells and other cell types Main source is unclear | (13, 14, 48) |
| **IL-30**           | gp130     | STAT1, STAT3, MAPK       | Inhibit Th1, Th17 differentiation | Activated Mø splenocytes | (15–18) |
| **IL-31**           | IL-31RA+OSMR | STAT1, STAT3, STAT5, PI3K, MAPK | Induce Th1, inhibit Th17 differentiation | Th cells | (19, 21) |
| **OSM**             | gp130+OSMR or gp130+LIFR | JAK, STAT3, MAPK, PI3K, PKCβ | Induce Th17 activation induces dendritic cell maturation and Th1 polarization | Activated Monocytes/Mø, DCs, neutrophils, T-lymphocytes. Hematopoietic cells in the bone marrow | (22, 23, 25, 26) |
| **LIF**             | gp130+LIFR | JAK1, JAK2, TYK2, STAT1, STAT3, STAT5, PI3K, MAPK | Prompt Th17 differentiation Inhibit Th17 differentiation | Tregs | (27, 28) |
| **CNTF**            | CNTF+gp130+LIFR | JAK, STAT1, STAT3, MAPK, PI3K | - | - | (29, 49, 50) |
| **CT-1**            | LIFR+gp130 or LIFR+gp130+CT-1R | JAK1, JAK2, TYK2, STAT1, STAT3, STAT5, MAPK, PI3K | Inhibit M1 polarization Prompt M2 polarization | Cardiac nonmyocytes | (30–33) |
| **CLC**             | CNTF+LIFR+gp130 | JAK1, JAK2, TYK2, STAT1, STAT3, MAPK, PI3K | Stimulate B cell Activate Mø Inhibit monocytes number | Circulating lymphocytes | (34, 35, 37–39) |

*Ma*, macrophages; DC, dendritic cell.
velocity (PWV) and can predict cardiovascular morbidity and mortality in hypertension patients. Clinical data shows a positive relationship between IL-6 and PWV (90–93). Du, Bing et al. showed that the LDLr-/- mice had larger PWV and ex vivo intrinsic mechanical properties, which means that LDLr-/- mice had arterial stiffness. IL-6 from aortic perivascular adipose tissue (PVAT) plays a critical role in promoting arterial stiffness. What’s more, the inhibition of IL-6 can attenuate arterial stiffness, and the treatment of IL-6 can aggravate (94).

Interleukin-6 Family Members and Aortic Aneurysms and Aortic Dissection
Aortic aneurysms are dilations of the aorta larger than 50% of the normal aorta diameter (95). Abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs) are the most common aortic aneurysms (96). Acute aortic dissection (AD) is a rare disease but has high mortality. The blood penetrates the aortic wall layers and creates a so-called false lumen (FL), which is a cavity within the medial layer. The FL and true lumen (TL) are separated by dissection membranes. The rupture of the FL or a second tear in the dissection membrane would cause serious consequences (97).

The expression of IL-6 is increased in β-aminopropionitrile (BAPN)-induced AD rat models. Circulating plasma IL-6 levels are increased in AAA patients. Experimental data support that aortic aneurysms can secrete IL-6 (98–100). Paige et al. found that selective inhibition of the IL-6 trans-signaling pathway can decrease aortic rupture and death in 2 AAA mouse models, which shows us a potential therapeutic target for AAA (101). The expression of IL-6 is increased in AD rat models. IL-6 may enhance the expression of MMP-2 and may promote extracellular matrix degradation of the vascular wall, which promotes the formation of AD (98). Lv, Xiao-Chai et al. found that plasma IL-6 level is elevated in postoperative delirium (POD) patients after aortic dissection surgery. Thus, plasma IL-6 values can be used to evaluate ADA patients’ POD outcomes (102). Besides, the high level of IL-6 and D-dimer has predictive value in assessing the poor prognosis after acute Stanford type A aortic dissection surgery (103). IL-11 is significantly increased in thoracic AD and can be a potential biomarker for AD (104). OSM is a proinflammatory mediator and is upregulated in abdominal AD patients. Thus, it may contribute to the development of aortic aneurysms (105, 106). The level of CT-1 is higher in AAA tissues. CT-1 can stimulate aortic endothelial cells to overproduce MMP-1, which leads to ECM degradation. These mechanisms are associated with the formation and progression of AAA (107, 108).

Interleukin-6 Family Members and Cardiac Remodeling
Cardiac fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) proteins that results in the expansion of the cardiac interstitium, which is a common pathophysiologic companion of most myocardial diseases. It is related to cardiac dysfunction, arrhythmogenesis, and adverse outcomes (109, 110). Cardiomyopathy is a disease that weakens the heart muscle, attenuating the heart’s ability to pump blood and possibly leading to heart failure (HF) (111). HF is a complex clinical syndrome that is caused by structural or functional impairment of ventricular filling or ejection of blood (112). Proinflammatory cytokines trigger a series of pathological responses, such as oxidative stress, endothelial dysfunction, induction of myocyte apoptosis, and hypertrophy, which ultimately leads to cardiomyocyte dysfunction (113).

An experimental study showed that IL-6 plays a central role in myocardial fibrosis that depends on the activation of the MAPK and CAMKII-STAT3 pathways. IL-6 is a downstream signal of hypoxia-induced mitogenic factor (HIMF), and its inhibition can prevent fibroblast activation (114). In addition, the overexpression of IL-6 increases TGF-β1-mediated MMP2/MMP3 signaling to induce myofibroblastic proliferation, differentiation, and fibrosis (115). IL-6 KO mice had a lower degree of cardiac fibrosis. Thus, anti-IL-6 can be a potential therapeutic target for decreasing cardiac fibrosis (116). The expression of IL-11 is positively related to myofibroblast numbers and is higher in mice with cardiac fibrosis than in wild-type mice (117). Anti-IL-11 treatment can attenuate the profibrotic effect on the heart of transverse aortic constriction (TAC) mouse model (118). Interestingly, Obana et al. found that IL-11 attenuates cardiac fibrosis in mouse models after myocardial infarction through the activation of STAT3 (119). Thus, when faced with different diseases, the appropriate application of IL-11 or its antagonist is a potential therapeutic target and needs further investigation. The antifibrotic effects of OSM are achieved by inhibiting the TGF-β1-mediated activation of cardiac fibroblasts in TAC mouse models (120). LIF cDNA injection was found to attenuate cardiac fibrosis in mice after myocardial infarction (121). Chronic administration of LIF improves the heart function of mice (122). Therefore, LIF may be a novel treatment for cardiac fibrosis. López et al. found that CT-1 can be a biomarker of myocardial fibrosis (123). CT-1 is believed to promote the development of cardiac fibrosis by upregulating Gal-3 through the ERK 1/2 and STAT3 pathways (124).

Clinical data have demonstrated that idiopathic dilated cardiomyopathy patients with higher serum IL-6 have a lower ejection fraction and worse prognosis (125). Serum IL-6 concentration is increased in patients with takotsubo cardiomyopathy (126). IL-6 KO mice with dilated cardiomyopathy showed better cardiac function and less myocardial cell apoptosis than WT mice with dilated cardiomyopathy because of the inhibition of STAT3 (127). The inhibition of IL-6/STAT3 signaling pathway may offer a new target for cardiomyopathy. Diabetic cardiomyopathy mice exhibited increased OSM. Moreover, OSM-treated diabetic mice exhibit worse cardiac function. Knockout of the OSM receptor Oββ attenuated dilated cardiomyopathy injury by inhibiting the B-Raf/MEK/ERK cascade (128). OSM is consistently upregulated in dilated cardiomyopathy patients and mouse models. OSM protects the damaged myocardium by inducing dedifferentiation. However, prolonged stimulation with OSM prompts the progression of HF in dilated cardiomyopathy (129). The plasma levels of CT-1 are increased in hypertrophic
cardiomyopathy and are associated with the severity of left ventricular hypertrophy (130). The expression of CT-1 is increased in the acute stage of Chagas disease (131). The plasma level of CT-1 is increased in dilated cardiomyopathy patients with congestive HF compared to control subjects (132).

An observational study showed that higher IL-6 plasma levels were found in half of HF patients and were associated with reduced left ventricular ejection fraction (LVEF), atrial fibrillation, and poorer clinical outcomes (133, 134). Genetic deletion of IL-6 alleviates left ventricular dysfunction through the STAT3 pathway in a transverse aortic constriction-induced pressure overload-HF mouse model (135). Moreover, the inhibition of IL-6/STAT3 by raloxifene can attenuate inflammation in the same model (136). Higher plasma IL-11 levels predict poor outcomes in HF patients (137). Plasma OSM levels are elevated in HF patients with reduced ejection fraction (HFrEF) (138). Kubin, Thomas et al. found that OSM is the key modulator of HF that induces cardiomyocyte dedifferentiation and contractility loss through the MAPK cascade in a mouse model of left anterior descending coronary artery (LAD) ligation (129). LIF mRNA is elevated in the left ventricle of congestive HF patients, and the circulating LIF level is increased with the deterioration of congestive HF (139, 140). Moreover, the upregulation of LIF in the ventricle was reproduced in the Dahl salt-sensitive (DS) rat chronic HF model (141). Myocardial and circulating CT-1 levels are increased in HF patients and are positively correlated with HF patient mortality, which can be used as a biomarker for determining prognosis (124, 142–144). CT-1 upregulates galectin-3 (Gal-3) via the ERK 1/2 and STAT3 pathways to promote cardiac fibrosis and hypertrophy, which are involved in the development of HF (124). López, Natalia et al. illustrate that LIFR is downregulated in spontaneously hypertensive rats HF model that attenuates the cytoprotection of CT-1. The upregulation of LIFR might be a potential target (145).

### Interleukin-6 Family Members and Atrial Fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia and leads to detrimental consequences. Increasing evidence supports that inflammation plays a crucial role in the pathophysiology of AF (146, 147). Thus, the process of inflammation is a potential therapeutic target for AF.

Amdur et al. found that elevated levels of IL-6 are associated with an increased risk of AF in chronic kidney disease (CKD) patients, which suggests that IL-6 can serve as an inflammatory biomarker for AF in CKD patients (148). Also, IL-6 levels are associated with AF in CAD patients (149). Elderly patients who received recombinant human IL-11 were observed to have an increased incidence of AF (150). OSM is increased in atrial tissue of AF patients with thrombus (151). Patients with higher levels of CT-1 have more frequent AF relapse (152). The correlation between the IL-6 family and AF still needs further study.

| Disease | IL-6 | IL-11 | OSM | CT-1 | Reference |
|---------|------|-------|-----|------|-----------|
| AS      | Increase - | Increase | Increase | (69, 71, 78) |
| CAD     | Increase - | Increase - | (63, 73) |
| Hypertension | Increase - | - | Increase | (85, 87, 88) |
| AA, AD  | Increase | Increase | Increase | (98–100, 104, 105, 108) |
| Cardiomyopathy | Increase | Increase | Increase | (126, 129, 131, 132) |
| AF      | Increase | Increase | Increase | (148, 151, 152) |
| Myocarditis | - | - | Increase | (159) |

**TABLE 2 | The expression of IL-6 family members on cardiovascular diseases.**

| Disease | IL-6 | IL-11 | OSM | CT-1 | Reference |
|---------|------|-------|-----|------|-----------|
| AS, atherosclerosis; CAD, coronary artery disease; I/R, ischemic-reperfusion; AA, arterial aneurysm; AD, aortic dissection; AF, atrial fibrillation.

### Interleukin-6 Family Members and Myocarditis

Myocarditis is an uncommon but potentially life-threatening heart disease (153). Myocarditis induces a broad range of pathological immune processes in the heart, which causes structural and functional abnormalities (154).

IL-6 plays a key role in the development of autoimmune heart disease, possibly by upregulating complement C3. IL-6 KO mice with autoimmune myocarditis showed a reduction in inflammatory responses, the proliferation of autoreactive CD4+ T cells, and the expression of ICAM-1 and VCAM-1, which reduced myocarditis susceptibility (155). IL-6 is crucial for Th17 differentiation through the induction of retinoic acid receptor-related orphan nuclear receptor, which is a critical event in the onset of experimental autoimmune myocarditis (EAM). The blockade of IL-6R inhibits the initiation of EAM (156). Adequate levels of IL-6 attenuate the damage from viral infection in the early stage of inflammation. Nevertheless, overexpression of IL-6 aggravates viral myocarditis (157). CT-1 is expressed in cardiac myocytes infected with Coxsackievirus B3 (CVB3) and induces pathologic responses in acute myocarditis. However, the early expression of CT-1 might have a protective effect on cardiac myocytes by inhibiting TNF-α and IL-1α expression (158).

### Interleukin-6 Family Members and Cardiac Ischemia Reperfusion Injury

Reperfusion of the myocardium can induce further cardiomyocyte apoptosis after cardiac ischemia, such as occurs with myocardial infarction or heart transplantation (159). Many studies have shown that myocardial apoptosis mediated by inflammation is one of the crucial processes of ischemia–reperfusion (I/R) injury (160, 161).

IL-6 prompts the development of infarction after cardiac I/R injury, whereas IL-6 deficiency attenuates I/R injury. However, the beneficial effects cannot be explained by modification of other inflammatory mediators, coagulation activation, or neutrophil influx. The related mechanisms need to be further explored (162). The administration of IL-11 has a protective effect on the heart from I/R injury via the STAT3 pathway. Thus, it can be a potential therapeutic target against I/R injury (163,
### TABLE 3 | Regulation of IL-6 family members on cardiovascular disease.

| Disease         | IL-6  | IL-11 | OSM    | LIF   | CT-1   | CLC   | Reference                  |
|-----------------|-------|-------|--------|-------|--------|-------|----------------------------|
| AS              | Aggravate | -     | Controversial | Alleviate | Aggravate | Aggravate | (44, 60, 71, 74, 75, 77) |
| CAD             | Aggravate | -     | Alleviate | -     | -      | -     | (65, 74)                  |
| Hypertension    | Aggravate | -     | -      | -     | Aggravate | -     | (83, 89, 135)            |
| AA, AD          | Aggravate | -     | -      | Aggravate | -     | -     | (98, 101, 105–108)       |
| Cardiac fibrosis| Aggravate | Controversial | -     | Alleviate | Aggravate | -     | (114–117, 121, 122, 124) |
| Myocarditis     | Aggravate | -     | -      | -     | -      | Controversial | (155, 156, 158) |
| Cardiomyopathy  | -     | -     | -      | -     | -      | Controversial | (129)                 |
| I/R             | Aggravate | Alleviate | Alleviate | Alleviate | Alleviate | Alleviate | (162–170)                |

AS, atherosclerosis; CAD, coronary artery disease; I/R, ischemic-reperfusion; AA, arterial aneurysm; AD, aortic dissection; AF, atrial fibrillation.

---

**FIGURE 1** | The relationship between IL-6 and atherosclerosis, MI, and vascular calcification. The IL-6 trans-signaling activates the JAK/STAT pathway that leads to chronic inflammation. It increases the adhesion molecules in the vasculature, endothelial dysfunction, the recruitment of monocytes/macrophages, and SMC migration. Monocytes uptake LDL and transform into foam cells that accelerate the progression of atherosclerosis. These pathological processes cause lipid deposition, plaque development, and plaque destabilization. With increasing severity of atherosclerosis, the plaque ruptures, and thrombosis result in myocardial infarction. IL-6 upregulates RUNX2 and RANKL/RANK, which induces the differentiation of VSMC to osteoblast and then induces the calcium-phosphate complexes deposition. JAK, Janus Kinase; STAT, Signal transducers and activators of transcription; LDL, Low-density lipoprotein; RUNX2, Runt-related transcription factor 2; RANKL, Receptor activator of NF-κB ligand; SMC, Smooth muscle cell; VSMC, Vascular smooth muscle cell.

164). OSM is thought to be an important factor for tissue repair after cardiac I/R injury because it upregulates monocyte-chemoattractant-protein (MCP-1) expression and stimulates the proliferation of fibroblasts (165). Experimental data show that OSM protects the heart against cardiac I/R injury through the regulation of mitochondrial biogenesis, cardiomyocyte apoptosis, and insulin sensitivity in diabetic mice (166). OSM can alleviate cardiac dysfunction and reduce the infarct size in mice partly through the Notch3/Akt and AMPK/PGC-1α pathways (167). Pretreatment with LIF has a protective effect on the heart against cardiac I/R injury (168). The significant protective effect that CT-1 has on the heart after I/R injury depends on the activation of the p42/p44 MAPK pathway (169, 170).
Interleukin-6 Family Members and Other Cardiovascular Diseases

IL-6 family members are also associated with other cardiovascular diseases, such as ventricular fibrillation, congenital heart disease (CHD), and vascular calcification.

Elevated IL-6 serum levels are correlated with the occurrence of spontaneous ventricular tachycardia and ventricular fibrillation in implantable cardioverter-defibrillator (ICD)-recipient patients with CAD and idiopathic dilated cardiomyopathy (171). The IL-6 variant rs1800795 is associated with CHD among Chinese Han people (172). Moreover, serum IL-6 levels are higher in CHD groups than in control groups (173, 174). Myocardial IL-11 and IL-6 levels are elevated in CHD children and downregulate the microRNA-199a-5p-mediated unfolded protein response through the STAT3 pathway (175). CT-1 is induced in CHD patients and is negatively correlated with arterial oxygen saturation (176). Clinical data show serum IL-6 levels are elevated in hemodialysis patients and chronic kidney disease patients with vascular calcification (177–180). IL-6 promotes vascular calcification by inducing the differentiation of VSMCs into osteoblast-like cells. IL-6/STAT3 pathway regulates RUNX2 gene expression, which is an important transcription factor of the differentiation of osteoblast (181). The activation of IL-6-mediated receptor activator of NF-κB ligand(RANKL) plays a crucial role in the development of vascular calcification. And the anti-IL-6 treatment can reduce the SMC calcification (182–184). Moreover, Lee, Guan-Lin et al. also showed the inhibition of IL-6 can attenuate the VSMC calcification (185).

CONCLUSION

This review describes the molecular receptors of the IL-6 family members, related signaling pathways, and their role in the regulation of inflammation. IL-6 family signal transduction is similar and is dominantly mediated by STAT3. The expression and regulation of IL-6 family members in cardiovascular disease are summarized in Tables 2, 3. Some family members, especially IL-6, have both pro- and anti-inflammatory effects through different receptors and pathways. Thus, the selective inhibition of trans-signaling rather than global inhibition might be a future therapeutic strategy. Cytokines affect the progression of cardiac pathology by regulating complex signaling networks. We illustrated the relationship between IL-6 and atherosclerosis, MI, and vascular calcification in Figure 1. Further research is needed to discover potential therapeutic targets and biomarkers for cardiovascular disease.

AUTHOR CONTRIBUTIONS

YF and DY wrote this article. ZW, HP, XL, MW, YX, JYU, JZ, MZ, SX, WP, and ZY searched the literature. JYe and JW provided ideas and financial support. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from National Natural Science Foundation of China (82070436).

REFERENCES

1. Roth GA, Johnson C, Abjoibor A, Abd-Allah F, Abra SE, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to (2015) J Am Coll Cardiol. (2017) 70. doi:10.1016/j.jacc.2017.04.052
2. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circulation Res. (2017) 121:677–94. doi:10.1161/CIRCRESAHA.117.308903
3. Ruparelia N, Chai JT, Fisher EA, Choudhury R. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nature reviews. Cardiology. (2017) 14:133–44. doi:10.1038/nrcardio.2016.185
4. Heinrich PC, Behrmann I, Haan S, Hermans HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical J. (2003) 374. doi:10.1042/bj20030407
5. Unver N, McAllister F. IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev. (2018) 41:10–17. doi:10.1016/j.cytogfr.2018.04.004
6. Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. (2018) 10. doi:10.1101/chspress.c028415
7. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature reviews. Immunology. (2018) 18:773–89. doi:10.1038/s41577-018-0066-7
8. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. (2019) 50:1007–23. doi:10.1016/j.immuni.2019.03.026
9. Leonard H. Calabrese and Stefan Rose-John, IL-6 biology: implications for clinical targeting in rheumatic disease. Nature reviews Rheumatology. (2014) 10:720–7. doi:10.1038/nrrheum.2014.127
10. Modares NF, Polz R, Haghighi F, Lamertz L, Behnke K, Zhuang Y, et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy. Hepatology (Baltimore, Md.). (2019) 70:675–91. doi:10.1002/hep.30774
11. Zeggey MM, Lindkvist M, Falkner K, Kumawat AK, Paramel G, Grenegard M, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells Cell Commun Signal. (2018) 16:55. doi:10.1186/s12964-018-0268-4
12. Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. (2015) 26:475–487. doi:10.1016/j.cytogfr.2015.07.004
13. Quintana FJ. Old dog, new tricks: IL-6 cluster signaling promotes pathogenic T17 cell differentiation. Nature Immunology. (2016) 18. doi:10.1038/nri.3637
14. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxaemia and obesity-associated resistance to insulin. Nature Immunology. (2014) 15:423–30. doi:10.1038/ni.2865
15. Braune J, Weyer U, Hohenfels C, Mauer J, Brüning JC, Ingel Bechmann, et al. IL-6 regulates M2 polarization and local proliferation of adipose tissue macrophages in obesity. J Immunol. (Baltimore, Md.: 1950). (2017) 198:2927–34. doi:10.4049/jimmunol.1600476
16. Atia-Kachoie P, Pourgholamii MH, Morris DL. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev. (2013) 24:163–173. doi:10.1016/j.cytogfr.2012.09.001
17. Obeng HH, Wesch D, Grossel S, Rose-John S, Kabela D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25+ and CD25high regulatory T cells. Int Immunol. (2006) 18:553–63. doi:10.1093/intimm/dkh396
Feng et al. IL-6 Family Members Involved in CVD

18. Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer letters. (2016) 373:156–63. doi: 10.1016/j.canlet.2016.01.004

19. Koch L, Kesphol B, Agthe M, Schumertl T, Düsterhöft S, Lemberg MK, et al. Interleukin-11 (IL-11) receptor cleavage by the rhomboid protease BHHD2 induces IL-11 trans-signaling. FASEB J. (2021) 35:e21380. doi: 10.1096/fj.202002087R

20. Metcalfe RD, Putoczki TL, Griffin MDW. Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: focus on interleukin 11. Front Immunol. (2020) 11:1424. doi: 10.3389/fimmu.2020.01424

21. Liu X, Wang Z, Ye N, Chen Z, Zhou X, Teng X, et al. A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. Biochem. Biophys. Res. Commun. (2013) 435:306–12. doi: 10.1016/j.jbc.2013.03.136

22. Stumhofer JS, Tait ED, Quinn WJ, Hosken N, Spudy B, Goenka R, et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The Chemistry of CNTF. (2015) 26:533–44. doi: 10.1016/j.cytogfr.2015.07.001

23. Yan J, Mitra A, Hu J, Cutrer JA, Xia X, Cutrer JJ, Xia X, Doetschman T, et al. Interleukin-30 (IL30) alleviates experimental sepsis by modulating cytokine profile in cardiothrophin-1 (CT-1) receptor signaling. J Immunol (Baltimore, Md.: 1950). (2010) 184:1378–85. doi: 10.4049/jimmunol.1502314

24. Murdaca G, Greco M, Tonacci A, Negrini S, Borro M, Puppo F, et al. IL-30 and IL-31 in immunity and cancer. Front Immunol. (2019) 10:2133. doi: 10.3389/fimmu.2019.02133

25. Pasquin S, Tormo A, Moreau J, Laplante V, Sharma M, Gauchat JE; et al. Cardiotrophin-like cytokine factor 1 exhibits a myeloid-biased hematopoietic-stimulating function. Front Immunol. (2019) 10:2133. doi: 10.3389/fimmu.2019.02133

26. Zlotides G, Gitzmman K, Stallak GA, Auernhammer CJ. Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC)—a novel gp130 cytokine with pleiotropic functions. Cytokine Growth Factor Rev. (2004) 15:325–36. doi: 10.1016/j.cytogfr.2004.04.002

27. Cui Y, Dai W, Li Y, Circulating levels of gp130 and sex hormones in male patients with coronary atherosclerotic disease. Atherosclerosis. (2017) 266:151–7. doi: 10.1016/j.atherosclerosis.2017.09.002

28. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nature reviews. Immunology. (2008) 8:337–48. doi: 10.1038/nri2295

29. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger M, Sindone G, et al. Critical clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Th17) in patients with colorectal cancer. Cancer Res. (2011) 71:1263–71. doi: 10.1158/0008-5472.CAN-10-2907

30. Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grötzing J, et al. Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha receptor for CNTF. J Biological Chemistry. (2003) 278:9528–35. doi: 10.1074/jbc.M210044200

31. Fontone S, Tossetta G, Montroni R, Senzaucchi T, Marzioni D, Mazucchelli R. Ciliary neurotrophic factor (CNTF) and its receptor (CNR) signal through MAPK/ERK pathway in human prostate tissues: a morphological and biomolecular study. Eur J Histochim: EHJ. (2020) 64. doi: 10.4081/ehj.2020.3147

32. Wen R, Tao W, Wiwen Li, and Paul A. Sieving, CNTF and retina. Progress in retinal and eye research. (2012) 31:136–151. doi: 10.1016/j.preteyeres.2011.11.005

33. Ma B, García-Cenador, J. M. Lopez-Novoa, J. Diez, and F. J. Garcia-Criado. Effects and mechanism of organ protection by cardioprotin-1. Current medicinal chemistry. (2013) 20:246–256. doi: 10.2174/092986713804806702

34. Carneiro D, Santamaría EM, Laredo E, Valdez-Ortiz JM, Reboredo M, Manchero U, et al. Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization. FASEB J. (2019) 33:7578–87. doi: 10.1096/fj.201801563R

35. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto Y, et al., Involvement of cardioprotin-1 in cardiac myocyte-nonnmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation. (1999) 100:1116–24. doi: 10.1161/01.CIR.100.11.1116

36. Stejskal D, Ruzicka V. Cardiotrophin-1. Review. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc. Czechoslovakia. (2008) 152. doi: 10.5507/bp.2008.002

37. Larsen JV, Kristensen AM, Pallesen LT, Bauer J, Vægt CB, Nielsen MS, et al. Cytokine-like factor 1, an essential facilitator of cardioprotin-like cytokine:cardiotrophin-like cytokine receptor signaling and sorgtLR-mediated turnover. Mol Cellular Biol. (2016) 36:1272–86. doi: 10.1128/MCB.00917–15

38. Elson GC, Lelièvre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nature Neuroscience. (2000) 3:867–72. doi: 10.1038/7875

39. Kass DJ, Yu G, Loh KS, Savir A, Borczuk A, Kahloon R, et al. Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antibiotic role in bleomycin injury. Am J Pathol. (2012) 180:1963–78. doi: 10.1016/j.ajpath.2012.01.010

40. Pasquin S, Laplante V, Koudri S, Milasan A, Mayer G, Tormo AJ, et al. Cardiotrophin-like cytokine increases macrophage-focal cell transition. J Immunology (Baltimore, Md.: 1950). (2018) 201:2462–71. doi: 10.3390/jmms2018008003

41. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto Y, et al. Cardiotrophin-like cytokine factor 1 exhibits a myeloid-biased hematopoietic-stimulating function. Front Immunol. (2019) 10:2133. doi: 10.3389/fimmu.2019.02133

42. Pasquin S, Tormo A, Moreau J, Laplante V, Sharma M, Gauchat JE; et al. Cardiotrophin-like cytokine factor 1 exhibits a myeloid-biased hematopoietic-stimulating function. Front Immunol. (2019) 10:2133. doi: 10.3389/fimmu.2019.02133

43. Pasquin S, Tormo A, Moreau J, Laplante V, Sharma M, Gauchat JE; et al. Cardiotrophin-like cytokine factor 1 exhibits a myeloid-biased hematopoietic-stimulating function. Front Immunol. (2019) 10:2133. doi: 10.3389/fimmu.2019.02133
Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med.* (1999) 340:115–26. doi: 10.1056/NEJM19990114400207

Okazaki S, Sakaguchi M, Miwa K, Furukado S, Yamagami H, Yagita Y, et al. Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study. *Stroke.* (2014) 45:2924–9. doi: 10.1161/STROKEAHA.114.005991

Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. *Cardiology Rev.* (2014) 22:147–51. doi: 10.1097/CRD.0000000000000021

Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. *Thrombosis and Haemostasis.* (2009). 102:215–22. doi: 10.1160/TH09-05-0297

Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. *Circulation Res.* (2004) 94:354–41. doi: 10.1161/01.RES.0000115557.25127.d8

Groot HE, Ali LA, Iwan C, Horst V, Schurer RAJ, van der Werf HW, et al. Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. *Clin Res Cardiol.* (2010) 98:14–18. doi: 10.1016/j.amjcard.2006.01.045

Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. *Thrombosis and Haemostasis.* (2009). 102:215–22. doi: 10.1160/TH09-05-0297

Wallentin L, Siegbahn A. Relationship between interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. *Am J Cardiol.* (2006) 98:14–18. doi: 10.1016/j.amjcard.2006.01.045

Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. *JAMA.* (2001) 265:2107–13. doi: 10.1001/jama.265.17.2107

Fisman EZ, Benderley M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with unstable coronary artery disease. *Clin Res Cardiol.* (2006) 95:343–41. doi: 10.1161/01.RES.0000115557.25127.d8

Li X, Zhang X, Wei L, Xia Y, Guo X. Relationship between serum oncostatin M and mortality in patients with unstable coronary artery disease: a single center study. *YES.* (2012) 62:942–50. doi: 10.1016/HYPERTELENAH.11.027

Miteva K, Baptista D, Monteczucato F, Asrani M, Burger F, Roth A, et al. Cardiovascular disease: deficiency abrogates atherosclerosis progression. *Scientific Reports.* (2020) 10:5791. doi: 10.1038/s41598-020-62596-6

Wilhelm J, Madea B, Mancini J, McIlroy W, Peduzzi P, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature.* (1997) 386:292–6. doi: 10.1038/386292a0

Kim JW, Markovich D, Sperber RW, Wu J, Bae WG, Huang PS, et al. Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand. *Proc Natl Acad Sci U S A.* (2020) 117:1410–11. doi: 10.1073/pnas.1927291117

Fisman EZ, Benderley M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. *Am J Cardiol.* (2010) 98:14–18. doi: 10.1016/j.amjcard.2006.01.045

Cleveland O, Kunszt G, Bratle M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. *Eur Heart J.* (2016) 37:2406–13. doi: 10.1093/eurheartj/ehw171

Fisman EZ, Benderley M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. *Am J Cardiol.* (2006) 98:14–18. doi: 10.1016/j.amjcard.2006.01.045

Huber SA, Conze SD, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. *Arterioscler Thromb Vasc Biol.* (1999) 19:2364–7. doi: 10.1161/01.ATV.19.10.2364

Schieffer B, Selle T, Hilfler A, Hilfler-Kleiner D, Grote K, Tietge UJ, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. *Circulation.* (2004) 110:3493–500. doi: 10.1161/01.CIR.0000148135.08582.97

Madinan M, Bishayi B, Hoge M, Amer S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an Apoe heterozygote murine model. *Atherosclerosis.* (2008) 197:504–14. doi: 10.1016/j.atherosclerosis.2007.02.023

Albasanz-Puig A, Marmier J, Preusch M, Coan D, Namekata M, Patel Y, et al. Oncostatin M is expressed in atherosclerotic lesions: a role for Oncostatin M in the pathogenesis of atherosclerosis. *Atherosclerosis.* (2011) 216:2928–34. doi: 10.1016/j.atherosclerosis.2011.02.003

Zhang X, Li J, Qi J, Cheng WL, Zhu X, Gong FH, et al. Oncostatin M receptor β deficiency attenuates atherosclerosis by inhibiting Jak2/Stat3 signaling in macrophages. *J Lipid Res.* (2017) 58:895–906. doi: 10.1194/jlr.M074112

Li X, Zhang X, Wei L, Xia Y, Guo X. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease. *Clinical Lab.* (2014) 60:113–8. doi: 10.7778/clinlab.2013.121245

van Kullen D, Pouwer MG, Emilsion V, Matic IP, Pieterman EJ, Hedin U, et al. Oncostatin M reduces atherosclerosis development in Apoe−/Leiden.CETP mice and is associated with increased survival probability in humans. *Plos ONE.* (2019) 14:e0221477. doi: 10.1371/journal.pone.0221477

Rolle B, Stamatios S, World CJ, Brown L, Thomas AC, Bingley JA, et al. Leukaemia inhibitory factor retards the progression of atherosclerosis.
130. Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. *Eur Heart J.* (2011) 32:177–83. doi: 10.1093/eurheartj/ehq400

131. Chandrasekar B, Melby C, Pennica D, Freeman GL. Overexpression of cardiortrophin-1 and gp130 during experimental acute Chagasic cardiomyopathy. *Immunology Letters.* (1998) 61:89-95. doi: 10.1016/S0735-1097(98)00167-3

132. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. *J Am Coll Cardiol.* (2001) 38:1485–90. doi: 10.1016/S0735-1097(01)01576-5

133. Markoussis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. *Eur J Heart Failure.* (2019) 21:963–73. doi: 10.1002/ejhf.1482

134. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. *J Am Coll Cardiol.* (1998) 31:391–8. doi: 10.1016/S0735-1097(98)00494-4

135. Zhao L, Cheng G, Jin R, Afzal MR, Samanta A, Xuan YT, et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. *Circulation Research.* (2016) 118:1918–29. doi: 10.1161/CIRCRESAHA.116.308688

136. Hirota H, Izu M, Hamaguchi T, Sugiyama S, Murakami E, Fujii M, et al. Therapeutic administration of IL-11 exhibits the postconditioning effects in a heart donor model. *Inflammation Research.* (2011) 60:489-499. doi: 10.1007/s00011-016-0931-4

137. Celik A, Sahin S, Koc F, Karayakal B, Sahin M, Benli I, et al. Overexpression of interleukin-6 aggravates viral myocarditic impaired increase in tumor necrosis factor-alpha. *J Molecular Cellular Cardiology.* (2001) 33:1627–35. doi: 10.1006/jmcc.2001.1428

138. Okuno M, Nakagawa M, Shimada M, Saito M, Hishinuma S, Takihara K. Expressional patterns of cytokines in a murine model of acute myocarditis: early expression of cardiotrophin-1. *Lab Invest.* (2000) 80:433–40. doi: 10.1038/labinvest.3780048

139. Hausenofl D, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. *J Clinical Investigation.* (2012) 123. doi: 10.1172/JCI62874

140. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. *Am J Transplantation.* (2011) 11:640–8. doi: 10.1038/ajt.2011.89

141. Arslan F, Klein D, Pasternak G. Innate immune signaling in cardiac ischemia. *Nature reviews. Cardiology.* (2011) 8:292–300. doi: 10.1038/nrcardio.2011.38

142. Hong WC, Cate HT, Linnenbank AC, de Boer OJ, Reitsma PH, de Winter RJ, et al. Reduced acute myocardial ischemia-reperfusion injury in IL-6-deficient mice employing a closed-chest model. *Inflammation Research.* (2016) 65:489-499. doi: 10.1007/s00011-016-0931-4

143. Obana M, Miyamoto K, Murasawa S, Ikawa T, Hayama A, Yamashita T, et al. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. *Am J Physiology.* (2012) 303:H569–H577. doi: 10.1152/ajpheart.00060.2012

144. Tamura Y, Kohno H, Mohri T, Fujiy O, Matsumiya G. The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model. *Annals Cardiothoracic Surgery.* (2018) 7:10.21037/acs.2017.09.11

145. Gwechenberger MM, Moerel D, Pacher R, Huelmans M. Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair. *Croatian Medical Journal.* (2004) 45:149–57.

146. Sun D, Li S, Wu S, Zhang M, Zhang X, Wei L, et al., Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice.
by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity. J Cellular Mol Med. (2015) 19:1296–307. doi: 10.1111/jcmm.12501

167. Zhang M, Wang C, Hu J, Lin J, Zhao Z, Shen Z, et al., Notch3/Akt signaling contributes to OSM-induced protection against cardiac ischemia/reperfusion injury. Apoptosis. (2015) 20:1150–63. doi: 10.1007/s10495-015-1148-7

168. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol. (1995) 27:223–9. doi: 10.1016/S0022-2828(08)80021-1

169. Liao Z, Brar BK, Cai Q, Stephanou A, O’Leary RH, Pennica D, et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischemia and at reperfusion. Cardiovascular Res. (2002) 53:902–10. doi: 10.1016/S0008-6363(01)00531-4

170. Brar BK, Stephanou A, Liao Z/O’Leary R, Pennica D, Yellon DM, et al., Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischemia and at reoxygenation. Cardiovascular Res. (2001) 51:265–74. doi: 10.1016/S0008-6363(01)00294-2

171. Streitner F, Kuschyk J, Veltmann C, Brueckmann M, Streitner I, Brade J, et al., Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipient— a pilot study. Cytokine. (2007) 40:30–34. doi: 10.1016/j.cyto.2007.07.187

172. Zhang Q, Wang H, Xue J, Wu D. Associations between IL-6 variations and congenital heart disease incidence among chinese han people. Med. Sci. Monit. (2020) 26:e921032. doi: 10.12659/MSM.921032

173. Wang D, Fang J, Wang R, Sun D, Xia K, Yin K, et al., Elevated serum ghrelin, tumor necrosis factor-α and interleukin-6 in congenital heart disease. Pediatr Int. (2016) 58:259-264. doi: 10.1111/ped.12773

174. Afify MF, Mohamed GB, El-Maboud MA, Abdel-Latif EA. Serum levels of ghrelin, tumor necrosis factor-alpha and interleukin-6 in infants and children with congenital heart disease. J Tropical Pediatrics. (2009) 55:388–92. doi: 10.1093/ troped/ftp036

175. Zhou Y, Pang B, Xiao Y, Zhou S, He B, Zhang F, et al. The protective microRNA-199a-5p-mediated unfolded protein response in hypoxic cardiomyocytes is regulated by STAT3 pathway. J Physiology Biochemistry. (2019) 75:73–81. doi: 10.1007/s41305-018-0657-6

176. Heying R, Qing M, Schumacher K, Sokalska-Duhrme M, Vazquez-Jimenez JF, Seghaye MC. Myocardial cardiotrophin-1 is differentially induced in congenital cardiac defects depending on hypoxemia. Future Cardiology. (2014) 10:53–62. doi: 10.2217/fca.13.99

177. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szymilak D, et al., Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrolgy, Dialysis, Transplantation. (2007) 22:515–521. doi: 10.1093/ndt/gfl364

178. Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, Kuo CC, et al., Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Disease Markers. (2013) 34:229-235. doi: 10.1155/2013/846059

179. Roy N, Rosas SE. IL-6 is Associated with Progression of Coronary Artery Calcification and Mortality in Incident Dialysis Patients. Am J Neuro. (2021) 52: 745–52. doi: 10.1159/000518652

180. Kaminski J, Stopiński M, Mucha K, Jedrzejczak A, Golebiowski M, Niewczas MA, et al. IL-6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine. (2019) 120. doi: 10.1016/j.cyt.o.2019.04.002

181. Kurozumi A, Nakano K, Yamaga K, Okada Y, Nakayamada S, Tanaka Y. IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through MJD2B-mediated histone demethylation of RUNX2. Bone. (2019) 124:33–61. doi: 10.1016/j.bone.2019.04.006

182. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research. (2004) 95:1046–57. doi: 10.1161/01.RES.0000149165.99974.12

183. Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL and interleukin-6 in congenital heart disease. J Tropical Pediatrics. (2009) 55:388–92. doi: 10.1093/ troped/ftp036

184. Yokota K, Sato K, Miyazaki T, Aizaki Y, Tanaka S, Sekikawa M, et al. Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis. Arthritis Rheumatology (Hoboken, N.J.). (2021) 73:1145–54. doi: 10.1002/art.41666

185. Lee GL, Yeh CC, Wu YJ, Lin HC, Wang YF, Kuo Yy, et al., TLR2 Promotes vascular smooth muscle cell chondrogenic differentiation and consequent calcification via the concerted actions of osteoprotegerin suppression and IL-6-mediated RANKL induction. Arterioscler Thromb Vasc. (2019) 39:432–45. doi: 10.1161/ATVBAHA.118.311874

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.